PubMed Health⌕ Search

Biomedical subjects

W M Valenti

Publications and source records attributed to W M Valenti.

At least 19 recordsLinked to original sources

Treatment adherence improves outcomes and manages costs.

Our experience with other chronic diseases, such as hypertension, diabetes, and asthma, has shown that adherence to treatment over time is about 50%. In HIV treatment, a significantly higher rate of adherence (i.e., 95% or greater) is required to achieve good outcomes. HAART is effective and cost-effective. Even with the high cost of antiretroviral drugs, the decrease in hospital utilization in addition to improved quality of life with HAART more than offsets the increased cost of drugs. This cost shifting from hospital utilization has been shown to result in a decrease of total monthly costs of care in many settings. In addition to decreased mortality and cost savings from decreased hospital utilization associated with HAART, the appropriate use of expensive antiretroviral drugs and the resultant reduction in antiretroviral resistance can save lives and money over the long term. However, we know that the performance of drugs in clinical trials is not always borne out in today's real world of ambulatory HIV care, underscoring the need for treatment adherence strategies in the HAART era. Our understanding of what improves adherence to antiretroviral treatment is still incomplete. However, there are a number of approaches that address the patient, the provider/multidisciplinary team, and the treatment regimen itself. The dedicated TAC, while not the only solution, has been shown to be an effective team member and a solution worth considering in managed care settings. When added to the costs of today's care, this team member should still prove cost-effective in the final analysis.

Anti-HIV Agents↗

HAART is cost-effective and improves outcomes.

An agenda for health care reform is well beyond the scope of this column. However, the agenda for providers of HIV care in managed care settings is clear. On a programmatic level, we know many of the solutions already. For example, there are published data supporting the role of experienced providers for HIV care. Outcomes are improved when patients with HIV receive care from "experts" (i.e., providers with experience in managing the disease). HAART improves outcomes; patients live longer and have more sustained viral load suppression, and costs of care are lower. Adherence to HAART is also beneficial and results in the same improved outcomes. The use of newer technologies to select these expensive antiretroviral regimens also results in these improved outcomes. Early treatment to which patients are adherent, access to experienced HIV providers, and a multidisciplinary program that delivers that care and the needed wraparound services make sense. In the era of HAART, it is often said that HIV is a chronic, manageable illness. Unfortunately, this applies to only a segment of the HIV-infected population. The findings of Freedberg and Bozzette and their colleagues continue to support a model of well-timed, well-coordinated HIV care. While this model of care is expensive, it is less expensive than inpatient care or the resultant poorer outcomes in the underserved, in nonadherent patients, or in those whose care is delivered by less experienced providers. There is no price to be placed on improved quality of life.

Antiretroviral Therapy, Highly Active↗

Impact of terrorist acts on HIV care: opportunities for program assessment and strategic planning.

HIV/AIDS providers need to take the time now to assess the current and future impact of the recent terrorist acts and biologic events on HIV programs. In addition to the efforts of HIV providers, both the public and private sectors have made an investment of billions of dollars since the start of the epidemic. We cannot afford to lose ground in the fight against HIV/AIDS. It is critically important to sustain and build on the improved outcomes--decreased mortality and fewer hospitalizations--that we have seen during the past 10 years. Access to care, advances in treatment, and biomedical technology have evolved to the point where HIV can be a chronic medical problem for many patients. Now, it is up to us as a medical community to continue this work.

Bioterrorism↗

HIV, managed care, and outcomes.

While it is not intended or cannot be encyclopedic, this article should provide a template for those who are starting a quality measurement program and resources where more information can be obtained. Key resources include the HIV/AIDS Bureau of the HHS, the Johns Hopkins AIDS Program, the Forum for Collaborative HIV Research, the HIV Cost and Services Utilization Study, and the growing initiative of the Infectious Diseases Society of America (IDSA). The IDSA also plans to address quality on a more global level, beyond the individual program. In a discussion of its HIV Quality Care Network, the IDSA reminds us that there is also a rationale beyond volume, practice, and outcome. As the IDSA continues its efforts at measuring outcomes, it will also develop data on cost and outcomes in different delivery systems to assist with appropriate public policy concerning the care of HIV-infected patients. It is hoped that this will allow all of us to influence public policy to improve the quality of care for HIV/AIDS patients and to achieve fair compensation for providers. Quality and outcomes measurement are important tools for managed care survival. Quality measurement also provides a link among providers, health care administrators, and payers. These data provide valuable information on program activities and effectiveness and are good for all of us, especially for patients.

Data Collection↗

Improving outcomes and managing costs of care: from the XIII International AIDS Conference.

Taken as a group, these presentations endorse a treatment strategy that should improve outcomes for patients as well as manage the high costs of antiretroviral therapy. A combination of strategies that balances antiretroviral therapy with convenient, compact regimens and the use of new technologies such as viral load monitoring, therapeutic drug levels, and resistance testing can lead to improved outcomes such as fewer hospitalizations and decreased mortality. Wrapped around this strategy is an adherence program that assesses adherence and provides treatment support by helping patients overcome the myriad barriers to adherence. When one compares the treatment of HIV in developed nations with that in underdeveloped nations, the contrasts can be sobering and stark as evidenced by the descriptions of the significant barriers to treatment in other parts of the world. It is clear that while we still have significant barriers to treatment in the United States, the rest of the world looks to us for answers on how to make treatment accessible and cost-effective.

Acquired Immunodeficiency Syndrome↗

Errors in medicine: problems and solutions for managed care.

Extrapolating data from 2 large retrospective studies, the IOM report provides an estimate of errors in health care. While these estimates have been taken from inpatient experience and not from ambulatory care (the site of most HIV/AIDS care today), these estimates have stimulated discussion and action on the part of the Federal government and health care organizations to improve patient safety. HIV/AIDS care lends itself to electronic solutions as suggested in the IOM report. Providers are under increasing pressure to do more clinical work and documentation in an era of shrinking resources. Managing the care of patients with HIV/AIDS requires frequent visits and necessitates documentation of both clinical and nonclinical information and considerable coordination and tracking of care activities by all members of the care team, with the goals of good outcomes and cost-effectiveness. Recent studies suggest that the current standard of HIV care is effective and cost-effective. Today's electronic technologies can help sustain these good outcomes by helping to manage large volumes of critical health information more efficiently. Electronic management of health information requires a change in work patterns and a significant capital investment for health organizations. Federal standards for management of electronic health information are in early implementation stages. To start the process, managed care organizations and HIV/AIDS providers should become familiar with the capabilities of electronic health information systems, begin the planning and needs assessment processes, and begin to lay the infrastructure needed for such systems.

Acquired Immunodeficiency Syndrome↗

HIV care is effective and cost-effective.

Standards of HIV care change to reflect new treatments and new technologies. Many of the studies cited here represent cost shifting rather than true cost savings. Either way, managed care organizations and HIV providers need to keep up with evolving standards of care, incorporate new treatments and technologies, and find ways to reconcile quality and good outcomes, all while managing the high costs of care.

Cost-Benefit Analysis↗

Product evaluation.

As healthcare budgets shrink, infection control personnel must become more involved in the process by which their institutions choose products and equipment. This article suggests an approach that individuals or programs can use to assess products in a consistent and thorough manner.

Blood-Borne Pathogens↗

Infection control and the pregnant health care worker.

Health care workers are constantly exposed to infectious agents in the course of their work. The pregnant health care worker presents additional concerns because of the potential risk of transmission of infection to the developing fetus. This article addresses the aspects of infection transmission, infectious agents of concern to health care workers, and operational aspects of an infection control program that is comprehensive, scientifically based, and equitable to all employees.

Environmental Microbiology↗